Drug Profile
Nilotinib nanoparticle formulation - Xspray Pharma
Alternative Names: HyNap-Nilo; RightSize nilotinib; XS 003Latest Information Update: 24 Nov 2023
Price :
$50
*
At a glance
- Originator Xspray Pharma
- Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Imidazoles; Ketones; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 21 Nov 2023 Nilotinib nanoparticle formulation is still in phase-I trials for Cancer (In volunteers) in United Kingdom
- 21 Nov 2023 Xspray Pharma plans to file NDA for Cancer in USA in the second half of 2024
- 21 Nov 2023 Pharmacokinetics data from phase-I trial in Cancer (In volunteers) released by Xspray Pharma